UBS Group’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-68,216
| Closed | -$616K | – | 11226 |
|
|
2025
Q4 | $616K | Sell |
68,216
-459,076
| -87% | -$3.43M | ﹤0.01% | 5954 |
|
|
2025
Q3 | $1.64M | Buy |
527,292
+159,783
| +43% | +$423K | ﹤0.01% | 5146 |
|
|
2025
Q2 | $786K | Buy |
367,509
+57,897
| +19% | +$93.5K | ﹤0.01% | 5640 |
|
|
2025
Q1 | $356K | Sell |
309,612
-3,472,971
| -92% | -$5.96M | ﹤0.01% | 6117 |
|
|
2024
Q4 | $8.28M | Buy |
3,782,583
+2,585,197
| +216% | +$5.86M | ﹤0.01% | 3267 |
|
|
2024
Q3 | $2.61M | Buy |
1,197,386
+1,175,766
| +5,438% | +$2.7M | ﹤0.01% | 3737 |
|
|
2024
Q2 | $49.9K | Sell |
21,620
-37,899
| -64% | -$157K | ﹤0.01% | 6690 |
|
|
2024
Q1 | $327K | Buy |
+59,519
| New | +$272K | ﹤0.01% | 5512 |
|
|
2023
Q4 | – | Sell |
-193
| Closed | -$6.7K | – | 9935 |
|
|
2023
Q3 | $6.7K | Sell |
193
-42,437
| -100% | -$1.47M | ﹤0.01% | 7279 |
|
|
2023
Q2 | $1.4M | Buy |
42,630
+42,346
| +14,911% | +$1.46M | ﹤0.01% | 3905 |
|
|
2023
Q1 | $9.52K | Sell |
284
-945
| -77% | -$36.7K | ﹤0.01% | 7646 |
|
|
2022
Q4 | $40.3K | Buy |
+1,229
| New | +$36.4K | ﹤0.01% | 6971 |
|
|
2022
Q3 | – | Sell |
-2,052
| Closed | -$25K | – | 10981 |
|
|
2022
Q2 | $25K | Sell |
2,052
-816
| -28% | -$12.2K | ﹤0.01% | 6618 |
|
|
2022
Q1 | $39K | Sell |
2,868
-932
| -25% | -$12.5K | ﹤0.01% | 6743 |
|
|
2021
Q4 | $76K | Buy |
+3,800
| New | +$72K | ﹤0.01% | 6543 |
|
Other funds holding VTYX
UBS Group's VTYX Position: Q1 2026 in Review
UBS Group sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 68,216 shares — an estimated $616K sold.
UBS Group first reported a position in VTYX in Q4 2021 and held it in 15 quarters. The position peaked at $8.28M in Q4 2024. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- UBS Group reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 68,216 Ventyx Biosciences shares in Q1 2026, an estimated $616K.
- UBS Group first reported a position in Ventyx Biosciences in Q4 2021 and held it in 15 quarters.
- UBS Group's Ventyx Biosciences position peaked at $8.28M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.